Basic HTML Version
49
Wytyczne postępowania u chorych leczonych doustnymi inhibitorami czynników IIa i Xa
www.angiologia.pl
Force for the Management of Atrial Fibrilation of the
European Society of Cardiology (ESC). Europace, 12:
1360–1420.
16. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns
HJGM (2010) Refining clinical risk stratification for
predicting stroke and thromboembolism in atrial
fibrilation using a novel risk factor-based approach:
the Euro Heart Survey on Atrial Fibrilation. Chest,
137: 263–272.
17. Lip GY (2010) Anticoagulaton therapy and the risk of
stroke in patients with atrial fibrillation at “moderate
risk” [CHADS2 score = 1]: simplifying stroke risk
assessment and thromboprophylaxis in real-life clinical
practice. Thromb Haemost, 103: 683–685.
18. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ,
LipGY (2010) A novel user-frendly score (HAS-BLED) to
assess one year risk of major bleeding in atrial fibrillation
patients: The EuroHeart Survey. Chest, 138: 1093–1100.